Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aptevo Therapeutics ( (APVO) ) just unveiled an update.
On September 4, 2025, Aptevo Therapeutics announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451, aimed at treating prostate cancer and other solid tumors with unmet needs. This development enhances Aptevo’s CD3 oncology pipeline and positions the company as a leader in next-generation T cell engagers, potentially offering profound treatment options by engaging multiple immune pathways to combat tumors effectively.
The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.
Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. The company utilizes proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to create therapeutic candidates targeting both hematologic and solid tumor cancers.
Average Trading Volume: 2,249,460
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.26M
See more data about APVO stock on TipRanks’ Stock Analysis page.